Abstract |
Bosutinib is an oral, dual SRC/ABL tyrosine kinase inhibitor (TKI) with clinical activity in Philadelphia chromosome-positive (Ph(+)) leukemia. We assessed the safety and tolerability of bosutinib 500 mg per day in a phase 1/2 study in chronic-phase (CP) chronic myeloid leukemia (CML) or advanced Ph(+) leukemia following resistance/intolerance to imatinib and possibly other TKIs. Patient cohorts included second-line CP CML (n = 286), third-/fourth-line CP CML (n = 118), and advanced leukemia (n = 166). Median bosutinib duration was 11.1 (range, 0.03-83.4) months. Treatment-emergent adverse events (TEAEs) in each cohort were primarily gastrointestinal ( diarrhea [86%/83%/74%], nausea [46%/48%/48%], and vomiting [37%/38%/43%]). Diarrhea presented early, with few (8%) patients experiencing grade 3/4 events; dose reduction due to diarrhea occurred in 6% of affected patients. Grade 3/4 myelosuppression TEAEs were reported in 41% of patients; among affected patients, 46% were managed with bosutinib interruption and 32% with dose reduction. Alanine aminotransferase elevation TEAEs occurred in 17% of patients (grade 3/4, 7%); among patients managed with dose interruption, bosutinib rechallenge was successful in 74%. Bosutinib demonstrated acceptable safety with manageable toxicities in Ph(+) leukemia. This trial (NCT00261846) was registered at www.ClinicalTrials.gov (this manuscript is based on a different data snapshot from that in ClinicalTrials.gov).
|
Authors | Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H Jean Khoury, Tim H Brümmendorf, Kimmo Porkka, Giovanni Martinelli, Simon Durrant, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Carlo Gambacorti-Passerini |
Journal | Blood
(Blood)
Vol. 123
Issue 9
Pg. 1309-18
(Feb 27 2014)
ISSN: 1528-0020 [Electronic] United States |
PMID | 24345751
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aniline Compounds
- Benzamides
- Nitriles
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Quinolines
- bosutinib
- Imatinib Mesylate
- Protein-Tyrosine Kinases
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Aniline Compounds
(adverse effects, therapeutic use)
- Benzamides
(therapeutic use)
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Drug-Related Side Effects and Adverse Reactions
(epidemiology, therapy)
- Female
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, epidemiology)
- Male
- Middle Aged
- Nitriles
(adverse effects, therapeutic use)
- Piperazines
(therapeutic use)
- Protein Kinase Inhibitors
(therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyrimidines
(therapeutic use)
- Quinolines
(adverse effects, therapeutic use)
- Withholding Treatment
(statistics & numerical data)
- Young Adult
|